Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice

Journal of Virology

Volumn 73, Issue 7, 1999, Pages 5981-5993

  Schell, Todd D ^a   Mylin, Lawrence M ^a   Georgoff, Ingo ^b,c   Teresky, Angelica K ^b   Levine, Arnold J ^b,d   Tevethia, Satvir S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c WYETH AYERST RESEARCH   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; ONCOPROTEIN; VACCINIA VACCINE; VIRUS LARGE T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER RADIOTHERAPY; CHOROID PLEXUS TUMOR; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN VIRUS 40; SPLEEN CELL; TRANSGENE; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0032987983     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.7.5981-5993.1999     Document Type: Article

References (76)

1. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96.
2. Antón, L. C., J. W. Yewdell, and J. R. Bennink. 1997. MCH class I-associated peptides produced from endogenous gene products with vastly different efficiencies. J. Immunol. 158:2535-2542.
3. Bacik, I., J. H. Cox, R. Anderson, J. W. Yewdell, and J. R. Bennink. 1994. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide. J. Immunol. 152:381-387.
4. Blachere, N. E., Z. Li, R. Y. Chandawarkar, R. Suto, N. S. Jaikarai, S. Basu, H. Udono, and P. K. Srivastava. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186:1315-1322.
5. Blaney, J. E., Jr., E. Nobusawa, M. A. Brehm, R. H. Bonneau, L. M. Mylin, T.-M. Fu, Y. Kawaoka, and S. S. Tevethia. 1998. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. J. Virol. 72:9567-9574.
6. b-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones. Virology 195:62-70.
7. Brinster, R. L., H. Y. Chen, A. Messing, T. van Dyek, A. J. Levine, and R. D. Palmiter. 1984. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 37:367-379.
8. Cameron, R. B., P. J. Spiess, and S. A. Rosenberg. 1990. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin-2, and local tumor irradiation. Studies on the mechanism of action. J. Exp. Med. 171:249-263.
9. Campbell, A. E., F. L. Foley, and S. S. Tevethia. 1983. Demonstration of multiple antigenic sites of the SV40 translation rejection antigen by using cytotoxic lymphocyte clones. J. Immunol. 130:490-492.
10. Cavender, J. F., A. Conn, M. Epler, H. Lacko, and M. J. Tevethia. 1995. Simian virus 40 large T antigen contains two independent activities that cooperate with a ras oncogene to transform rat embryo fibroblasts. J. Virol. 69:923-934.
11. Chen, L. 1998. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol. Today 19:27-30.
12. Chouaib, S., C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J. Y. Blay. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18:493-497.
13. Ciernik, I. F., J. A. Berzofsky, and D. P. Carbone. 1996. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156:2369-2375.
14. Colby, W. W., and T. Shenk. 1982. Fragments of the simian virus 40 transforming gene facilitate transformation of rat embryo cells. Proc. Natl. Acad. Sci. USA 79:5189-5193.
15. b-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen. J. Virol. 66:440-447.
16. Faas, S. J., S. Pan, C. A. Pinkert, R. L. Brinster, and B. B. Knowles. 1987. Simian virus 40 (SV40)-transgenic mice that develop tumors are specifically tolerant to SV40 T antigen. J. Exp. Med. 165:417-427.
17. Feltkamp, M. C. W., H. L. Smits, M. P. M. Vierboom, R. P. Minnaar, B. M. de Jongh, J. W. Drijfhout, J. ter Schegget, C. J. M. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumour induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242-2249.
18. Feltkamp, M. C. W., G.R. Vreugdenhil, M. P. M. Vierboom, E. Ras, S. H. van der Burg, J. ter Schegget, C. J. M. Melief, and W. M. Kast. 1995. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25:2638-2642.
19. Fox, N., R. Crooke, L.-H.S. Hwang, U. Schibler, B. B. Knowles, and D. Solter. 1989. Metastatic hibernomas in transgenic mice expressing an α-amylase-SV40 T antigen hybrid gene. Science 244:460-463.
20. Fu, T.-M., L. M. Mylin, T. D. Schell, I. Bacik, G. Russ, J. W. Yewdell, J. R. Bennink, and S. S. Tevethia. 1998. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J. Virol. 72:1469-1481.
21. Fu, T.-M., R. H. Bonneau, M. J. Tevethia, and S. S. Tevethia. 1993. Simian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes. J. Virol. 67:6866-6871.
22. Fuchs, E. J., and P. Matzinger. 1996. Is cancer dangerous to the immune system? Semin. Immunol. 8:271-280.
23. Gairin, J. E., and M. B. A. Oldstone. 1992. Design of high-affinity major histocompatibility complex-specific antagonist peptides that inhibit cytotoxic T-lymphocyte activity: implications for control of viral disease. J. Virol. 66:6755-6762.
24. Ganss, R., and D. Hanahan. 1998. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 58:4673-4681.
25. Garrido, F., F. Ruiz-Cabello, T. Cabrera, J. J. Pérez-Villar, M. López-Botet, M. Duggan-Keen, and P. L. Stern. 1997. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18:89-95.
26. Geiger, T., G. Soldevila, and R. A. Flavell. 1993. T cells are responsive to the simian virus 40 large tumor antigen transgenically expressed in pancreatis islets. J. Immunol. 151:7030-7036.
27. k. J. Immunol. 129:1306-1312.
28. Guerder, S., E. E. Eynon, and R. A. Flavell. 1998. Autoimmunity without diabetes in transgenic mice expressing β cell-specific CD86, but not CD80: parameters that trigger progression to diabetes. J. Immunol. 161:2128-2140.
29. Guerder, S., D. E. Picarella, P. S. Linsley, and R. A. Flavell. 1994. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor a leads to autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA 91:5138-5142.
30. Hanahan, D. 1985. Heritable formation of pancreatic β-cell tumors in transgenic mice expressing recombinant insulins/simian virus 40 oncogenes. Nature 315:115-122.
31. Harlan, D. M., H. Hengartner, M. L. Huang, Y. H. Kang, R. Abe, R. W. Moreadith, H. Pircher, G. S. Gray, P. S. Ohashi, G. J. Freeman, et al. 1994. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc. Natl. Acad. Sci. USA 91:3137-3141.
32. Harlow, E., L. V. Crawford, D. C. Pim, and N. M. Williamson. 1981. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39: 861-869.
33. Heath, W. R., J. Allison, M. W. Hoffmann, G. Schönrich, G. Hämmerling, B. Arnold, and J. F. A. P. Miller. 1992. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature 359:547-549.
34. Jolicoeur, C., D. Hanahan, and K. M. Smith. 1994. T cell tolerance towards a transgenic β-cell antigen and transcription of endogenous pancreatic genes in the thymus. Proc. Natl. Acad. Sci. USA 91:6707-6711.
35. Kappler, J. W., N. Roehm, and P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273-280.
36. + thymocytes. Nature 333:742-746.
37. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459-465.
38. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736.
39. Lill, N. L., M. J. Tevethia, W. G. Hendrickson, and S. S. Tevethia. 1992. Cytotoxic T lymphocytes (CTL) against a transforming gene product sleet for transformed cells with point mutations within sequences encoding CTL recognition epitopes. J. Exp. Med. 176:449-457.
40. b-restricted cytotoxic T lymphocyte epitopes in simian virus 40 tumor antigen. J. Virol. 69:3134-3146.
41. Ljunggren, H.-G., and K. Kärre. 1985. Host resistance directed selectively against H-2-deficient lymphoma variants. J. Exp. Med. 162:1745-1759.
42. d by cytolytic T cells. Cell 58:293-303.
43. Manfredi, J. J., and C. Prives. 1994. The transforming activity of simian virus 40 large tumor antigen. Biochim. Biophys. Acta 1198:65-83.
44. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991-1045.
45. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. DeLeo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1297-1302.
46. + T cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54:4155-4161.
47. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. Sourdive. A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177-187.
48. b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69:6665-6677.
49. b-restricted determinant in simian virus 40 tumor antigen. Virology 208:159-172.
50. North, R. J. 1984. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol. Immunother. 16:175-181.
51. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malisseu, R. M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305-317.
52. Oldstone, M. B. A., M. Nerenberg, P. Southern, J. Price, and H. Lewicki. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65:319-331.
53. Palmiter, R. D. H. Y. Chen, A. Messing, and R. L. Brinster. 1985. SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumors in transgenic mice. Nature 316:457-460.
54. Pan, S., J. Abramczuk, and B. B. Knowles. 1987. Immune control of SV40-induced tumors in mice. Int. J. Cancer 39:722-728.
55. Restifo, N. P., F. Esquivel, A. L. Asher, H. Stotter, R. J. Barth, J. R. Bennink, J. J. Mulé, J. W. Yewdell, and S. A. Rosenberg. 1991. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J. Immunol. 147:1453-1459.
56. Rocha, B., and H. von Boehmer. 1991. Peripheral selection of the T cell repertoire. Science 251:1225-1228.
57. + T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model. J. Immunol. 161:5133-5137.
58. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321.
59. Salvucci, L. A., R. H. Bonneau, and S. S. Tevethia. 1995. Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes. J. Virol. 69:1122-1131.
60. Soldevila, G., T. Geiger, and R. A. Flavell. 1995. Breaking immunologic ignorance to an antigenic peptide of simian virus 40 large T antigen. J. Immunol. 155:5590-5600.
61. Speiser, D. E., R. Miranda, A. Zakarian, M. F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, and P. S. Ohashi. 1997. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-653.
62. b-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. Virology 171:205-213.
63. Tanaka, Y., and S. S. Tevethia. 1988. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J. Immunol. 140:4348-4354.
64. Tanaka, Y., and S. S. Tevethia. 199. Loss of immunorecessive cytotoxic T lymphocyte determinant V on SV40 T antigen following cocultivation with site-specific cytotoxic T lymphocyte clone Y-5. Intervirology 31:197-202.
65. Tevethia, S. S. 1990. Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes. Mol. Biol. Med. 7:83-96.
66. Tevethia, S. S., J. W. Blasecki, G. Waneck, and A. L. Goldstein. 1974. Requirement of thymus-derived θ-positive lymphocytes for rejection of DNA virus (SV40) tumors in mice. J. Immunol. 113:1417-1423.
67. Van Dyke, T. A., C. Finlay, D. Miller, J. Marks, G. Lozano, and A. J. Levine. 1987. Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J. Virol. 61:2029-2032.
68. von Herrath, M. G., J. Dockter, and M. B. A. Oldstone. 1994. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1:231-242.
69. von Herrath, M. G., S. Guerder, H. Lewicki, R. A. Flavell, and M. B. A. Oldstone. 1995. Coexpression of B7-1 and viral ("self") transgenes in pancreatic β cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. Immunity 3:727-738.
70. von Herrath, M. G., and M. B. A. Oldstone. 1997. Interferon-γ is essential for destruction of β cells and development of insulin-dependent diabetes mellitus. J. Exp. Med. 185:531-539.
71. Walker, P. R., P. Saas, and P. Y. Dietrich. 1997. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol. 158:4521-4524.
72. Webb, S., C. Morris, and J. Sprent. 1990. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63:1249-1256.
73. Wick, M., P. Dubey, H. Koeppen, C. T. Siegel, P. E. Fields, L. Chen, J. A. Bluestone, and H. Schreiber. 1997. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186:229-238.
74. Wortzel, R. D., J. L. Urban, and H. Schreiber. 1984. Malignant growth in the normal host after variant selection in vitro with cytolytic T-cell lines. Proc. Natl. Acad. Sci. USA 81:2186-2190.
75. Ye, X., A. Kralli, R. Ge, R. P. Ricciardi, and B. B. Knowles. 1994. Down-regulation of MHC class I antigen in insulinoma cells controlled by the R1 element of the H-2 enhancer. Oncogene 9:1195-1204.
76. Ye, X., J. McCarrick, L. Jewett, and B. B. Knowles. 1994. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. USA 91:3916-3920.